Biomedes Clear science, from bench to bedside

Biomedes

Clear science, from bench to bedside

Latest Articles

Calibration for a Country: Matching Diagnostic Validation to the UK's Population Mix
Diagnostics

Calibration for a Country: Matching Diagnostic Validation to the UK's Population Mix

A CE mark confirms that a device meets regulatory requirements; it does not confirm that the cohort behind the paperwork resembles the patients in front of you. With assay replacements continuing across UK laboratories in 2026, a structured local-validation protocol can close the distance between certification and clinical reality.
First Contact with a Number: A Laboratory Playbook for Direct-to-Patient Results
Diagnostics

First Contact with a Number: A Laboratory Playbook for Direct-to-Patient Results

Patients increasingly see blood and pathology results in portals before a clinician has called. For UK laboratories in 2026, that makes release rules, interpretive wording and escalation pathways part of the diagnostic safety case, not an afterthought for communications teams.
When the Bench Changes Hands: A Handover Standard for 24/7 UK Pathology
Diagnostics

When the Bench Changes Hands: A Handover Standard for 24/7 UK Pathology

Shift change is a clinical transition, not an administrative one. This article sets out why informal bench handover is a diagnostic safety risk in UK laboratories and proposes a one-page ledger that makes outstanding work visible without adding another meeting.
Diagnostics

Seeing the Same Thing Twice: Colour Assurance Before AI Enters UK Digital Pathology

Digital pathology promises resilient reporting and faster second opinions, but scanner colour variation can undermine AI validation and cross-site comparison. This article sets out the colour-assurance questions UK laboratories, vendors and commissioners should answer in 2026.
Before the Barcode: Why UK Pathology Ordering Screens Deserve a Safety Case
Diagnostics

Before the Barcode: Why UK Pathology Ordering Screens Deserve a Safety Case

Preanalytical failure is often treated as a specimen problem, yet many errors are shaped earlier by request forms and electronic ordering screens. This article argues that UK pathology ordering interfaces need device-style scrutiny, with a practical audit and redesign checklist for laboratories, primary care and IT teams.
Reagent Provenance as Translational Control: The Antibody Validation Gap in UK Laboratories
Medtech Translation

Reagent Provenance as Translational Control: The Antibody Validation Gap in UK Laboratories

Unvalidated antibodies rarely announce themselves as procurement failures. They reappear as irreproducible blots, wasted technician hours and grant milestones that cannot be defended. This article sets out a practical validation and lot-tracking framework for UK research teams buying reagents in 2026.
The Van, the Letterbox and the Assay: Validating UK Home-Sampling Kits for Real Transit
Medtech Translation

The Van, the Letterbox and the Assay: Validating UK Home-Sampling Kits for Real Transit

Home-sampling kits are moving into mainstream UK diagnostics, but a validation pack that stops at the laboratory bench leaves the most variable preanalytical step unexamined. This article sets out a practical transport-stability protocol for blood and saliva kits, from Royal Mail transit profiles to acceptance criteria and the documentation commissioners will expect.
Version Control for Susceptibility: Making Breakpoint Updates Visible in UK Laboratories
Diagnostics

Version Control for Susceptibility: Making Breakpoint Updates Visible in UK Laboratories

Annual antimicrobial susceptibility updates can reclassify organisms, alter cascade reporting and change clinician behaviour long after the validation paperwork has been filed. This deep dive examines how UK laboratories can manage EUCAST and CLSI revisions across the LIS, disc diffusion, automated systems and stewardship teams without creating invisible reporting inconsistencies.
Why 'Normal' Travels Poorly: Local Reference Intervals Before the Next UK Analyzer Replacement
Diagnostics

Why 'Normal' Travels Poorly: Local Reference Intervals Before the Next UK Analyzer Replacement

Vendor reference intervals are convenient defaults, not universal truths. As UK laboratories plan analyzer replacements, local verification and targeted de novo studies can prevent a new platform from redefining disease by configuration.
From Broad Consent to Model Cards: The Biobank Release Audit UK Research Teams Need
Medtech Translation

From Broad Consent to Model Cards: The Biobank Release Audit UK Research Teams Need

Requests to train AI models on biobank tissue and data expose a gap between broad research consent and machine-learning reuse. This release audit sets out the provenance, commercial-use, re-identification and model-documentation checks UK biobanks should complete before samples leave the freezer.
Before the Robot: Why Pathology Automation Should Begin With an Ethnography, Not a Business Case
Medtech Translation

Before the Robot: Why Pathology Automation Should Begin With an Ethnography, Not a Business Case

Vendor throughput claims are measured on a laboratory that does not exist. The informal workarounds and invisible handoffs that hold a real NHS pathology service together are the missing specification — and two weeks of structured observation is cheaper than buying the wrong machine.
Rapid Tests, Real-World Conditions: A Commissioner's Checklist for Community Point-of-Care Diagnostics
Diagnostics

Rapid Tests, Real-World Conditions: A Commissioner's Checklist for Community Point-of-Care Diagnostics

Point-of-care testing has moved from the margins of UK diagnostics to something closer to a front door. But a rapid test is not a small laboratory, and scaling community testing depends far less on the device than on the arrangements wrapped around it. A practical checklist for commissioners, pharmacy leads and laboratory teams.
The Ninety-Minute Gap: What Really Happens to a Blood Tube Inside the NHS
Diagnostics

The Ninety-Minute Gap: What Really Happens to a Blood Tube Inside the NHS

Between the needle and the result screen sits a chain of handoffs that few clinicians ever see. This explainer follows a single blood tube through a UK pathology network and examines where preanalytical error creeps in — and which interventions actually close the gap.
The False-Positive Problem: Why Sensitivity Alone Should Not Win an NHS Contract
Medtech Translation

The False-Positive Problem: Why Sensitivity Alone Should Not Win an NHS Contract

A test with excellent sensitivity can still generate more false positives than true ones once it meets a low-prevalence population. This analysis works through the arithmetic, draws on UK screening and lateral flow experience, and sets out the questions commissioners should ask before adoption.
Syndromic Testing at Scale: What UK Laboratories Need to Weigh Before the 2026 Winter Respiratory Surge
Diagnostics

Syndromic Testing at Scale: What UK Laboratories Need to Weigh Before the 2026 Winter Respiratory Surge

Multiplex respiratory panels are moving from specialist virology centres into routine NHS workflows. The science is elegant; the operational questions are harder, from validation and turnaround to antimicrobial stewardship.
Seven Quiet Bottlenecks in UK Medtech Translation - and the Questions That Surface Them Early
Medtech Translation

Seven Quiet Bottlenecks in UK Medtech Translation - and the Questions That Surface Them Early

Promising diagnostics and devices rarely fail on the science alone. They stall in the gaps between prototype, regulation and NHS adoption. Here are seven recurring bottlenecks, with UK-specific warning signs and questions to ask before budgets are committed.